On the evening of August 27th, the 2025 Frost & Sullivan Global Growth, Innovation and Leadership Awards, China Awards, and Best Practices Awards were grandly announced at the 2025 Frost & Sullivan Global Growth, Innovation and Leadership Awards Ceremony and VIP Reception.
Based on recent research and analysis of the global vaccine market, as well as studies and evaluations of related companies in the industry, Frost & Sullivan awarded Jiangsu Zhonghuiyuantong Biotechnology Co., Ltd. (hereinafter referred to as 'Zhonghuiyuantong') the '2025 Frost & Sullivan Global Vaccine Industry Annual Enterprise Award'. Robin Joffe, Partner at Frost & Sullivan and President of the Middle East, South Asia, and North Africa region, and Professor Wang Yu, President of the China Liver Disease Foundation, an expert advisor to the Frost & Sullivan Global Expert Advisory Group, and winner of the 2024 Frost & Sullivan Greater China Special Contribution Award, presented the award on behalf of Jiangsu Zhonghuiyuantong Biotechnology Co., Ltd.
Jiangsu Zhonghuiyuantong Biotechnology Co., Ltd.
"Global Vaccine Industry Awards 2025"
Robin Joffe, Partner at Frost & Sullivan and President of the Middle East, South Asia and North Africa region, and Professor Wang Yu, Chairman of the China Foundation for Hepatitis Prevention and Control, an expert advisor of the Frost & Sullivan Global Expert Advisory Group and winner of the 2024 Frost & Sullivan Greater China Special Contribution Award, presented awards on behalf of Jiangsu Zhonghuiyuan Tong Biotechnology Co., Ltd.
Zhonghuiyuantong is a leader in the quadrivalent influenza subunit vaccine market in China, driving the iterative upgrade of the vaccine industry with 'demand-driven + platform-based' strategies.
Jiangsu Zhonghuiyuan Tong Biotechnology Co., Ltd. was established in 2015 and is the only innovative vaccine company in China that holds registration numbers for quadrivalent influenza virus subunit vaccines for both children aged 3 and above and those aged 6-35 months. Relying on a closed-loop technical architecture of 'virus subunit purification - human diploid cell culture - polysaccharide conjugation', the company has built an end-to-end vaccine development and industrialization system covering four platforms: influenza, pneumonia, rabies, and mRNA. It has achieved large-scale implementation in both the upgrade of traditional vaccines and the research and development of innovative vaccines.
Utilize market demand-driven strategies to build a diversified vaccine pipeline
With a keen insight into international epidemic trends and unmet public health needs, Zhonghuiyuantong is market-oriented. Relying on its full-category vaccine development platform covering viral subunits, polysaccharide conjugates, human diploid cells, and mRNA technology, it continuously iterates and innovates to accelerate industrialization. The full-category vaccine development support platform has been supported by 37 patents. In addition to China's first quadrivalent influenza subunit vaccine, 11 other pipeline products are advancing simultaneously, forming a diversified product echelon covering high-incidence diseases such as respiratory tract, rabies, and pneumonia, thus building a sustainable competitive moat for the company.
Adhere to demand-driven innovation and promote the high-quality leapfrog development of the vaccine industry
Zhonghuiyuan continues to increase its investment in scientific research, jointly building the 'Subunit Vaccine Innovation Platform' with Shanghai/Taizhou dual R&D centers, provincial CDCs, and national-level projects, accelerating the clinical transformation of next-generation RSV, mRNA, and conjugate vaccine technologies. In the future, the company will take on the mission of 'ensuring that China has access to globally innovative vaccines and that the world has access to high-quality Chinese vaccines.' By continuously launching innovative vaccines with high protection, low side effects, and coverage across all age groups, the company aims to lead the industry towards upgrading towards higher-level subunits and precision prevention, contributing to the construction of a multi-level, sustainable immune barrier.
About the Frost & Sullivan Global Annual Corporate Awards
The Frost & Sullivan Global Annual Corporate Award recognizes outstanding performance and achievements in technological innovation, market potential, customer service, brand, and other aspects by companies. The Frost & Sullivan team has nominated a competitive group of excellent companies to the independent judging panel through methods such as in-depth interviews, industry analysis, and secondary research. An independent judging panel composed of third-party investment and financing experts, financial specialists, bankers, and renowned listed entrepreneurs conducts a rigorous review of the companies nominated by the Frost & Sullivan team, deciding to award the '2025 Global Vaccine Sector Annual Corporate Award' to Jiangsu Zhonghuiyuantong Biotechnology Co., Ltd.
